We reported that selective investigational SYK inhibitor entospletinib was safe and efficacious in patients with CLL when combined with obinutuzumab, an anti-CD20 antibody, or tirabrutinib, a BTK inhibitor [36, 37]. Here, SYK is linked to B-cell chronic lymphocytic leukemia.